VERU INC.
For the period ended Dec 17, 2025. Filed Dec 17, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Dec 17, 2025 · Filed Dec 17, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Summary
Summary
The Phase 2b QUALITY clinical trial confirms that preserving lean mass with enobosarm plus semaglutide led to greater fat loss during the active weight loss period, and after semaglutide was discontinued, enobosarm monotherapy significantly prevented the regain of both weight and fat mass such that by the end of the 28 week study there was greater loss of fat mass while preserving lean mass for a higher quality weight reduction compared to the placebo group.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.